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Malaria caused by Plasmodium falciparum is a disease that is responsible for 880,000 deaths per year 
worldwide. Vaccine development has proved difficult and resistance has emerged for most antimalarial 
drugs. To discover new antimalarial chemotypes, we have used a phenotypic forward chemical genetic 
approach to assay 309,474 chemicals. Here we disclose structures and biological activity of the entire 
library—many of which showed potent in vitro activity against drug-resistant P. falciparum strains—and 
detailed profiling of 172 representative candidates. A reverse chemical genetic study identified 19 new 
inhibitors of 4 validated drug targets and 15 novel binders among 61 malarial proteins. 
Phylochemogenetic profiling in several organisms revealed similarities between Toxoplasma gondii and 
mammalian cell lines and dissimilarities between P. falciparum and related protozoans. One exemplar 
compound displayed efficacy in a murine model. Our findings provide the scientific community with new 
starting points for malaria drug discovery. 
 
The widespread resistance of P. falciparum to many antimalarial drugs, the dependence of all new drug 
combinations on artemisinins (for which resistance may have emerged)1,2, and new efforts to eradicate 
malaria all drive the need to develop new, effective and affordable antimalarial drugs3. Although our 
understanding of the parasite’s biology has increased with the sequencing of the Plasmodium genome4 
and the development of new technologies to study resistance acquisition5–7, few new drug targets or 
classes of drugs have been clinically validated8. The lack of publicly accessible antimalarial chemotypes 
with differing modes of action has significantly hindered efforts to discover and develop new drugs9. To 
address this urgent need, we have developed a forward chemical genetic approach to identify novel 
antimalarials (Supplementary Fig. 1) 
The forward chemical genetic screen 
A library containing 309,474 unique compounds, designed at the scaffold level to provide diverse, 
comprehensive coverage of bioactive space10,11, was screened against Plasmodium falciparum strain 3D7 
at a fixed concentration of 7µM(Supplementary Information)12. Fidelity of the assay was examined by 
receiver operator characteristic (ROC) analysis and other metrics (Supplementary Figs 2 and 3), 
demonstrating good discriminatory power (area under the curve, 0.85) and indicating that a cutoff of ≥ 
80% activity would retain most of the true positives. The strength of the assay was further determined by 
testing a set of bioactive compounds including known antimalarials, all of which were re-identified 
(Supplementary Table 3), demonstrating that the method was very likely to identify any molecule acting 
by a known mechanism. The primary screen gave approximately 1,300 hits with activity ˃ 80%. These 
compounds were serially diluted and tested against both the chloroquine-sensitive 3D7 strain and the 
chloroquine-resistant K1 strain, giving 1,134 validated hits that had saturated dose–response curves. 
Chemical structure analysis of validated hits by topology mapping and clustering10 revealed a wide 
distribution of chemotypes in the active chemical space, with several displaying promising structure-
activity relationships (Fig. 1). Although all known antimalarial scaffolds (aminoquinolines, quinolones, 
bisamidines) present in the screening collection were identified, providing positive controls for the screen, 
most of the chemotypes identified were new. A total of 561 of the validated hits had half- maximum 
effective concentration (EC50) values ≤2µM against either 3D7 or K1 and a therapeutic window ≥ 10-fold 
against two mammalian cell lines (HepG2 and BJ). From this set, 228 structurally distinct, pure 
compounds were re-purchased in powder form for further studies. Antimalarial potencies of ~75% of 
these compounds (172) were reconfirmed to within tenfold (Bland–Altman analysis, Supplementary Fig. 
4) by three laboratories using distinct methods providing the cross-validated hit set used for all 
subsequent experiments. 
Combination with antimalarial drugs 
Owing to rapid resistance acquisition, the World Health Organization (WHO) recommends combination 
therapy13. The agonistic and antagonistic synergies of the cross-validated set were therefore quantified by 
measuring EC50 shifts in the presence of a fixed fraction of potency(EC10) concentration of chloroquine, 
mefloquine, artemisinin and atovaquone. Most cross-validated compounds were additive in effect or had 
minor synergies with existing drugs. Two classes demonstrated strong synergies (EC50 values reduced by 
≥ 10-fold): the diaminonaphthoquinones with artemisinin, and the dihydropyridines with mefloquine (Fig. 
2). One diaminonaphthoquinone and a cycloguanil analogue displayed antagonism with chloroquine and 
mefloquine, respectively.  
Reverse chemical genetics 
The advantages of phenotypic screens for the identification of novel chemotypes are that no a priori 
assumptions are made concerning drug targets and that active compounds inherently have cellular bio-
availability. Because insight into the mechanism of action is helpful for drug development, we also 
investigated the interaction of the cross-validated set with 66 potential targets using enzyme inhibition 
assays and thermal melt shift assays (to detect binding). 
Three high-priority, well characterized biological targets were evaluated in activity assays (Fig. 3, left): P. 
falciparum dihydroorotate dehydrogenase (PfDHOD), haemozoin formation and P. falciparum falcipain-
2 (PfFP-2). PfDHOD catalyses the oxidation of dihydroorotate to orotate in de novo pyrimidine 
biosynthesis, which is essential for parasite viability14,15. Three compounds inhibited this enzyme: two 
triazolopyrimidines, structurally related to known PfDHOD inhibitors with comparable potencies14, and a 
dihydropyridine, structurally related to the calcium blocker felodipine. The potency of these compounds 
against PfDHOD strongly correlated with their antimalarial activities (Supplementary Table 5). 
Furthermore, these compounds were inactive against transgenic parasites expressing Saccharomyces 
cerevisiae dihydroorotate dehydrogenase (Supplementary Table 6). Next, haemozoin formation inhibition 
was investigated. The parasite digests host haemoglobin to provide amino acids, detoxifying the resulting 
haem molecules by conversion to a crystallized form known ashaemozoin. Haem detoxification is 
believed to be the target of many antimalarial drugs16. Twelve compounds showed appreciable efficacy in 
an in vitro haemozoin formation assay17, including analogues of quinazoline, benzofuran, benzimidazole 
and carbazole as well as amodiaquine, a known haemozoin formation inhibitor present in our library. The 
correlation between enzyme inhibitory potency and antimalarial potency was similar to that displayed by 
the positive controls quinine and amodiaquine (Supplementary Table 5). The third enzyme assayed was 
PfFP-2, which has a critical role in haemoglobin degradation18 . Falcipains are redundant in P. 
falciparum, with four known homologues including two (falcipain-2 and falcipain-3) that seem to have 
key roles in erythrocytic stage parasites19. Three weakly active PfFP-2 inhibitors were identified. Thus, 19 
compounds (11%) were inhibitors of validated antimalarial targets.  
To expand the pool of potential targets, the compounds were tested for binding to 61 recombinant 
malarial proteins (95% purity or better after affinity and size exclusion chromatography; Supplementary 
Table 1) in a thermal melt shift assay20. Fifteen compounds displayed reproducible thermal shifts with 
seven malarial proteins (Fig. 3,right; dissociation constant (Kd) values in Supplementary Table 2): 6-
phosphogluconolactonase, 6-pyruvoyltetrahydropterin synthase, choline kinase, D-ribulose-5-phosphate3-
epimerase, dUTPase, glycogen synthase kinase 3 and thioredoxin. Two compounds bound multiple 
proteins. Two out of the seven proteins are in essential malarial pathways: phosphatidylcholine 
synthesis21 (choline kinase) and redox metabolism22 (thioredoxin). The remaining five protein targets 
potentially represent novel antimalarial drug targets. 
The potential for cross-resistance 
To evaluate the potential for cross-resistance with existing drugs, the cross-validated compounds were 
tested against a panel of P. falciparum strains with different chemosensitivities to known antimalarials, 
including strains 3D7 (chloroquine sensitive), K1, W2, V1/S and Dd2 (all resistant to both chloroquine 
and to antifolates), and SB-A6 and D10_yDHOD (both chloroquine sensitive and atovaquone resistant). 
All strains were profiled for sensitivity to a set of antimalarial drugs to normalize activity (Supplementary 
Table 3). A total of 58 cross-validated compounds displayed similar potencies (EC50 shift ≤ 3-fold) 
against 3D7, K1, V1/S and SB-A6, indicating that these compounds do not share mechanisms of 
resistance with chloroquine, atovaquone o rsulphadoxine/pyrimethamine. A subset of the 172 compounds 
that were inactive against drug-resistant P. falciparum strains with known mutations in target proteins 
were testedagainst3D7 dihydrofolate reductase and Plasmodium yoelii cytochrome bc1 complex in 
biochemical assays. Two inhibitors were identified for each protein (Supplementary Tables 5 and 6). 
Phylochemogenetic profiling 
To understand relationships between chemical sensitivity of Plasmodium and related parasites, the cross-
validated set was tested against three additional protozoan parasite species— Toxoplasma gondii, which 
belongs to the same phylum as Plasmodium (Apicomplexa), and Leishmania major and Trypanosoma 
brucei, which are both Kinetoplastida, unrelated to the Apicomplexa—and an expanded panel of human 
cell lines including a Burkitt’s lymphoma line (Raji) and embryonic kidney fibroblast cells 
(HEK293).Phylogenetic criteria predict that chemical sensitivity should correlate with evolutionary 
history, due to homology between key protein targets, as is known to be the case for many antiparasitic 
drugs23,24. Although a few compounds showed activity in other parasites, most were highly selective for 
Plasmodium (Fig. 4), whereas Toxoplasma exhibited a chemo-sensitivity pattern more similar to human 
cell lines. Similarly, the highly potent anti-leishmanial benzothiazoles were only weakly active against the 
related Trypanosoma. These findings indicate that chemical sensitivity of pathogens is regulated by a 
combination of pathogen genetics, physiology and relationships to host and vector species in vivo. 
Early leads for drug development 
To understand the potential for development of the novel chemotypes, the pharmacokinetic properties of 
the cross-validated set were assessed. The majority are reasonably drug-like, with 78% of com- pound 
shaving no violations of the Lipinski rule of five, a well validated predictor of oral bioavailability, and 
99% having one or fewer violations25. Within the cross-validated set were embedded three chemical series 
that had multiple members that together gave structure–activity relationships that spanned 1,000-fold 
potency differences, had con- sistent activity in drug-resistant strains, had very good cellular therapeutic 
windows, and had at least one member with an EC50 more potent than 50nM. An exemplar compound was 
selected from each series and fully profiled using standard models of in vitro and in vivo adsorption, 
distribution, metabolism and toxicity (Supplementary Table 7). Each possessed reasonable characteristics 
for developable hits; indeed, each comes close to passing Medicines for Malaria Venture (MMV) criteria 
for ‘late leads’. The compound from these exemplars with the best pharmacokinetic profile was further 
evaluated to measure in vivo antimalarial activity and displayed efficacy in a murine malaria model 
infected with P. yoelii. A twice-daily administration of 100mg kg-1 for 3 days resulted in a 90% 
suppression of the parasitaemia (Supplementary Fig. 5). Although it is not suggested that any of the 
compounds discussed herein are bone fide preclinical candidates, all provide reasonable starting points for 
drug development. 
Conclusions 
Drug therapy remains a key component in controlling malaria. Current challenges of rapid acquisition of 
resistance, cross-resistance and dependence on a limited number of chemical classes of antimalarials 
highlight the need to enhance our understanding of the ‘chemical space’ that can be brought to bear on 
malaria treatment. Solving this problem requires understanding the relationships between the structures of 
compounds active against malaria parasites, and their potency, selectivity and targets. We have identified 
a number of novel compounds and defined these relationships. We expect that these findings will provide 
novel paths for drug development and hope that making this set of well characterized, non-proprietary 
lead antimalarials publicly available to the global research community will help to reinvigorate drug 
discovery for malaria. 
METHODS SUMMARY 
The primary screen was carried out by comparing quantities of DNA in treated and control cultures of 
Plasmodium falciparum in human erythrocytes after 72h incubation with a fixed concentration of 7µM of 
the test compounds. The secondary potency determination was made by using the same assay in a dose–
response mode with 10 concentrations varying from 10µM to 5 nM. Chemical sensitivities of the human 
cell lines and T. brucei were determined by measuring their ATP content (Cell Titer Glo, Promega). T. 
gondii parasites expressing luciferase were cultured and drug sensitivity was determined by 
luminescence; L. major promastigote drug susceptibility was tested using a metabolic function assay 
(Alamar Blue, Promega). Chemicals were assayed for haemozoin formation17 and PfDHOD15 and PfFP-
226 inhibitory activities based on previously described methods. Thermal shift assays were done at 
ompound concentrations of 25µM and protein concentrations of 100µg ml-1. All data processing and 
visualization, and chemical similarity and substructure analysis, was performed using custom programs 
written in the Pipeline Pilot platform (Accelrys, v.7.0.1) and the R program27. A complete description of 
the methods can be found in Supplementary Information. 
The Supplementary Information provides a summary of all relevant data arising from the phenotypic 
screen and all secondary screens including relevant diagnostics and details about the following: cell-
based, enzyme and thermal shift screens, data processing, Bland–Altman analysis, and the algorithm to 
generate the chemical structure network graph. Chemical structures annotated with assay data and high-
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Figure 1 | Chemical structure network graph and antimalarial potencies of the 1,300 primary 
screen hits. Topologically similar molecules cluster together in the branches of the network. To construct 
the graph, molecules were first abstracted to scaffolds and then further to cores using the Murcko 
algorithm 10. Each of these structural entities is represented as a node, and nodes are connected via edges 
according to topological relationships with closeness being defined using the Tanimoto coefficient. 
Molecular nodes are coded to reflect potency against P. falciparum strains K1 (low, white; high, blue) 
and 3D7 (low, small; high, large). The highly branched structure of the full network graph (bottom half of 
the figure) indicates that the 1,300 compounds are organized into clusters of clusters: cores are well 
sampled by multiple scaffolds, and the cores themselves are grouped into families of related chemotypes. 
Previously reported antimalarial compounds are highlighted in the lower centre. The top half of the figure 
provides greater detail on three potent chemotypes with well-developed structure activity relationships: a, 





Figure 2 | Reduced representation of the network map showing synergistic activities with clinically 
relevant antimalarials. The size of the nodes reflects the magnitude of the logarithmic difference 
between EC50 in the presence and absence of EC10 of exemplar antimalarial drugs. Absolute differences 
less than one log unit were not considered significant. Synergistic and antagonistic compounds are 
uniformly colour-coded blue and red respectively. Highly synergistic compounds can be seen with 





Figure 3 | Reduced representation of the network map showing the interaction of the cross-
validated hits with potential biological targets. The network map on the left displays compounds 
targeting well-validated protein targets as measured in inhibition assays (EC50 # 15mM). The map on the 
right shows compounds that bind to purified malarial proteins according to thermal melt shift 
experiments. The size of nodes representing active or binding compounds is increased for clarity. Data are 




Figure 4 | Phylochemogenetic profiling. Phylochemogenetic analysis of the cross-validated compounds 
using a two-way hierarchical clustering of growth inhibition against P. falciparum strains (3D7, K1, 
V1/S), other eukaryotic parasites (Toxoplasma gondii (Tg), Trypanosoma brucei (Tb), Leishmania major 
(Lm)) and human cell lines (HEK293, BJ, Raji and HepG2). Columns represent single compounds and 
are clustered according to potency against the cell lines and organisms. Neighbouring compounds share a 
similar potency spectrum. Rows represent a single cell line or organism and are clustered according to 
their chemosensitivity to the compounds in the study. Aphylogenetic tree of the organisms in this study is 
provided for reference. Note that despite the many known examples of taxonomically conserved 
pathways, on a global level, phylogeny is a poor predictor of chemical sensitivity profiles: Toxoplasma 
responses more closely parallel human than their evolutionary siblings, Plasmodium. Data are in 
Supplementary Information. 
 
 
 
 
 
 
 
 
